Latest Headlines

  1. Novotech Releases In-Depth Report On Cervical Cancer: Addressing A Global Health Challenge 12/4/2024

    Boston, USA – Novotech, the global full-service clinical Contract Research Organization (CRO), has released a new report, Cervical Cancer - Global Clinical Trial Landscape. This report offers a comprehensive analysis of the global cervical cancer research landscape, highlighting the crucial role of clinical trials in advancing treatment options. It outlines key geographic trends, emerging therapies, and future projections, providing valuable insights for researchers and healthcare professionals working to combat this disease.

  2. Novotech And Biostar Establish Strategic Partnership Following Biostar's HKEX Listing 12/4/2024

    Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has announced a long-term strategic partnership with Beijing Biostar Pharmaceuticals Co., Ltd. (2563.HK) (“Biostar”). This collaboration strengthens the commitment of both companies to advance clinical research, leveraging Novotech’s expertise and technical platforms to support Biostar’s clinical development plans. 

  3. Show Chwan Health Care System Joins Hands With Novotech To Accelerate The Quality Of International Clinical Trials Of New Drugs 12/4/2024

    Show Chwan Health Care System announced that it has signed a Memorandum of Understanding (MOU) with Novotech, a clinical research organization (CRO) in the Asia-Pacific region. It will use Novotech’s experience in planning clinical trials to target Changhua and the introduction of new clinical trial cases in Tainan, which will help doctors and patients get in touch with the latest treatment technologies and shorten the development period of new drugs.

  4. Cellistic Announces Successful Certification Of Its GMP Facility Dedicated To iPSC-Based Cell Therapies 11/21/2024

    Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its first-of-its kind facility dedicated to manufacturing therapies based on induced pluripotent stem cells (iPSCs)

  5. Leading The Way: OpenClinica EDC Earns Major Recognition 11/18/2024
  6. AST Announces Quick Delivery For GENiSYS® C R&D Small Batch cGMP Filling & Closing System 11/13/2024

    Available for quick delivery, AST's Isolated GENiSYS® C is a fully integrated solution for the production of high-value liquid pharmaceuticals. Designed in collaboration with Germfree, and leveraging the latest American-made turnkey technology from AST, this production system is backed by a localized, responsive model for supply and service.

  7. Novotech Recognized For Excellence In Business Expansion, Innovation, And Marketing At The 2024 Clinical Trials Arena Excellence Awards 11/12/2024

    Novotech, the global full-service clinical Contract Research Organization (CRO), has received multiple awards in the 2024 Clinical Trials Arena Excellence Awards, recognizing the achievements of our people in Business Expansion, Innovation, and Marketing. These awards highlight our commitment to advancing the clinical trial landscape and delivering specialized solutions across the biotech sector.

  8. Show Chwan Health Care System Joins Novotech To Accelerate The Quality Of International Clinical Trials Of New Drugs 11/12/2024

    Show Chwan Health Care System announced that it has signed a Memorandum of Understanding (MOU) with Novotech, a clinical research organization (CRO) in the Asia-Pacific region. It will use Novotech’s experience in planning clinical trials to target Changhua and the introduction of new clinical trial cases in Tainan, which will help doctors and patients get in touch with the latest treatment technologies and shorten the development period of new drugs.

  9. Theragent And CellVax Therapeutics Announce First Patient Dosed In Phase 2 Trial of FK-PC101, A Novel Personalized Cancer Immunotherapy 11/11/2024

    Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax Therapeutics Inc. This past week, Theragent produced the first batch of autologous cancer vaccine to dose the first patient in CellVax Therapeutics' randomized Phase 2 clinical trial for FK-PC101.

  10. Avance Clinical CEO And Asia Director Sign MOUs With Key Clinical Trial Sites In Korea Around 2024 KoNECT 10/30/2024

    Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce the signing of three significant Memorandums of Understanding (MOUs) with key Korean clinical sites during KoNECT 2024 conference.